Oppenheimer Holdings Stock News

NASHUA, N.H., Dec. 06, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey Stevens, President and incoming Chief Executive Officer, will present a corporate overview at Oppenheimer’s Imagine AI + Healthcare Investor Summit being hosted by Oppenheimer in partnership with the Alliance for AI in Healthcare (AAIH).

Snowflake (NYSE:SNOW) had its target price boosted by Oppenheimer from $360.00 to $400.00 in a research report report published on Thursday morning, The Fly reports. They currently have an outperform rating on the stock. A number of other research analysts have also recently issued reports on SNOW. Deutsche Bank Aktiengesellschaft lifted their target price on []

Lululemon Athletica (NASDAQ:LULU) had its target price lifted by Telsey Advisory Group from $485.00 to $515.00 in a research report sent to investors on Friday morning, Stock Target Advisor reports. Telsey Advisory Group currently has an outperform rating on the apparel retailers stock. Other equities analysts have also recently issued reports about the company. Oppenheimer []

Broadcom (NASDAQ:AVGO) had its price objective boosted by Oppenheimer from $575.00 to $650.00 in a research note issued to investors on Friday morning, The Fly reports. Oppenheimer currently has an outperform rating on the semiconductor manufacturers stock. Several other equities analysts also recently weighed in on AVGO. Summit Redstone downgraded Broadcom to a hold rating [] The post Broadcom (NASDAQ:AVGO) Price Target Raised to $650.00 at Oppenheimer appeared first on ETF Daily News .

Ulta Beauty (NASDAQ:ULTA) had its target price boosted by Oppenheimer from $450.00 to $470.00 in a research note released on Friday morning, Analyst Ratings Network reports. The brokerage currently has an outperform rating on the specialty retailers stock. Oppenheimer also issued estimates for Ulta Beautys Q4 2022 earnings at $4.30 EPS, Q1 2023 earnings at [] The post Ulta Beauty (NASDAQ:ULTA) Given New $470.00 Price Target at Oppenheimer appeared first on ETF Daily News .

Ambarella, Inc. (NASDAQ:AMBA) Investment analysts at Oppenheimer issued their Q3 2023 EPS estimates for shares of Ambarella in a note issued to investors on Wednesday, December 1st. Oppenheimer analyst M. Yang anticipates that the semiconductor company will earn $0.10 per share for the quarter. Ambarella (NASDAQ:AMBA) last issued its quarterly earnings data on Tuesday, [] The post Ambarella, Inc. (NASDAQ:AMBA) to Post Q3 2023 Earnings of $0.10 Per Share, Oppenheimer Forecasts appeared first on ETF Daily News .

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)s stock price gapped up prior to trading on Friday . The stock had previously closed at $19.99, but opened at $21.56. PMV Pharmaceuticals shares last traded at $22.07, with a volume of 1,118 shares changing hands. A number of research analysts have issued reports on the company. Oppenheimer assumed coverage on []

Marvell Technology (NASDAQ:MRVL) had its price target hoisted by Oppenheimer from $100.00 to $110.00 in a research report sent to investors on Friday, The Fly reports. The firm currently has an outperform rating on the semiconductor companys stock. MRVL has been the topic of several other reports. KeyCorp increased their price objective on shares of []

Oppenheimer initiated coverage on shares of Harmony Biosciences (NASDAQ:HRMY) in a report published on Tuesday, Analyst Price Targets reports. The firm issued an outperform rating and a $55.00 price objective on the stock. Oppenheimer also issued estimates for Harmony Biosciences Q4 2021 earnings at $0.36 EPS, FY2021 earnings at $0.56 EPS, Q1 2022 earnings at []

Caribou Biosciences, Inc. (NASDAQ:CRBU) Oppenheimer issued their FY2021 earnings per share estimates for Caribou Biosciences in a research note issued on Tuesday, November 30th. Oppenheimer analyst M. Breidenbach expects that the company will post earnings of ($1.88) per share for the year. Oppenheimer currently has a Outperform rating and a $36.00 price target on [] The post Caribou Biosciences, Inc. Forecasted to Earn FY2021 Earnings of ($1.88) Per Share (NASDAQ:CRBU) appeared first on ETF Daily News .

UnitedHealth Group Incorporated (NYSE:UNH) Investment analysts at Oppenheimer lowered their FY2021 earnings per share (EPS) estimates for shares of UnitedHealth Group in a research report issued on Wednesday, December 1st. Oppenheimer analyst M. Wiederhorn now anticipates that the healthcare conglomerate will earn $18.85 per share for the year, down from their previous forecast of []

ATLANTA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- National investor fraud law firm KlaymanToskes (KT) announces it is preparing to file a FINRA arbitration claim against Oppenheimer & Co. (NYSE: OPY) on behalf of a former Delta Air Lines (NYSE: DAL) pilot who sustained over $1M in losses in Horizon Private Equity III. KT is focusing on Oppenheimers role in enabling the massive alleged Horizon Ponzi scheme devised by Marietta, Georgia resident and former Oppenheimer registered representative, John Woods, which was operated through his firm, Southport Capital.

Five Below (NASDAQ:FIVE)s stock had its outperform rating reaffirmed by analysts at Oppenheimer in a note issued to investors on Friday, The Fly reports. They currently have a $230.00 price target on the specialty retailers stock, up from their previous price target of $220.00. Oppenheimers target price would indicate a potential upside of 18.89% from []

Ulta Beauty (NASDAQ:ULTA) had its target price raised by stock analysts at Oppenheimer from $450.00 to $470.00 in a research report issued on Friday, Benzinga reports. The firm currently has an outperform rating on the specialty retailers stock. Oppenheimers price objective would suggest a potential upside of 22.51% from the stocks previous close. Other research []